Coherus BioSciences Inc

For the period ended Mar 31, 2025. Filed May 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 12, 2025

CHRS$0.64-21.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations


· · Three Months Ended
· · March 31,
· 2025 · 2024
Net revenue	$7,599	$2,308
Costs and expenses:
Cost of goods sold	2,653	1,439
Research and development	24,356	28,424
Selling, general and administrative	26,025	40,232
Total costs and expenses	53,034	70,095
Loss from operations	(45,435)	(67,787)
Interest expense	(2,150)	(3,118)
Other income (expense), net	187	2,869
Loss from continuing operations before income taxes	(47,398)	(68,036)
Income tax provision	—	—
Net loss from continuing operations	(47,398)	(68,036)
Net income (loss) from discontinued operations, net of tax (Note 6)	(9,171)	170,911
Net income (loss)	$(56,569)	$102,875

Net income (loss) per share:
Net loss from continuing operations - basic and diluted	$(0.41)	$(0.60)
Net income (loss) from discontinued operations - basic and diluted	$(0.08)	$1.52
Net income (loss) per share - basic and diluted	$(0.49)	$0.91

Weighted-average number of shares used in computing net income (loss) per share:
Basic and diluted	115,857,780	112,749,306

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.